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Sophie Hamel1,2*, Douglas S McNair3, Nicholas J Birkett1,4, Donald R Mattison1,5, Anthony Krantis2 and Daniel Krewski1,4,5Abstract
Purpose: To determine the level of off-label cancer therapy use in a population of female breast cancer patients
and to establish whether this use was evidence-based.
Methods: A study was conducted by sampling Cerner’s data warehouse for all women diagnosed with breast
cancer between January 2000 and June 2009 who received at least one cancer therapy approved by the US-FDA
during the study period. Drug encounters were considered off-label if the circumstances of use did not match the
age or medical diagnoses specified on the product label at the time of study. The level of evidence for the use of
these drugs in a breast cancer setting was evaluated from randomized phase III trials using a tiered approach.
Results: The study included 2,663 women with a median age of 59 years. A total of 1,636 off-label encounters were
recorded, representing 13.0% of all encounters. Of the 65 cancer therapies investigated, 55.4% were prescribed
off-label. The drugs with the highest off-label use were, in a descending order, vinorelbine, carboplatin, bevacizumab,
leuprolide, liposomal doxorubicin and cisplatin. Most off-label encounters were evidence-based and more likely to be
associated with private insurance coverage, younger age, ethnicities other than Caucasian, smaller treatment centres
and drugs with limited labeled indications that have a longer market history.
Conclusions: Off-label prescribing is common practice in oncology and is an integral component of breast cancer
treatment strategies. While this practice tends to be associated with specific socio-demographic factors and disease
characteristics, the majority of off-label encounters appear to be evidence-based.
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Women’s healthBackground
All prescription drugs are labeled in accordance with
the circumstances of use and evidence collected from
randomized controlled clinical trials. However, once a
drug reaches the market, a physician may exert clinical
judgement and prescribe drugs for other conditions or
circumstances. This type of prescribing is considered
'off-label’ and has become part of mainstream medical
practice extending beyond the specifications of the
drug label (American Society of Clinical Oncology
2006; Poole & Dooley 2004; United States General Ac-
counting Office 1991).* Correspondence: shame052@uottawa.ca
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in any medium, provided the original work is pOff-label use in breast cancer has been previously re-
ported (United States General Accounting Office 1991;
Delpeuch et al. 2011), but only one study has focused on
the off-label chemotherapeutic use in women over
65 years old diagnosed with breast cancer between 1991
and 2002 (Dean-Colomb et al. 2009). Although off-label
use of chemotherapy has been reported, breast cancer
patients are treated with a wide variety of agents which
are not considered typical chemotherapies. The discov-
ery of distinct molecular determinants of tumor develop-
ment and progression has opened a new era of targeted
therapies. Investigating the extent of off-label use, taking
into consideration the broader range of therapies avail-
able and extending the analysis to the overall breast can-
cer population, regardless of age, may provide insight
into the scope of this practice.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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label use of any chemotherapies, targeted agents, hor-
mone therapies, and immunotherapies approved by the
FDA as a cancer therapy at the time of this study and in-
vestigate whether drug coverage or factors such as patient
demographics, drug, treatment centre and physician char-
acteristics influence off-label prescribing among breast
cancer patients.
Results
Number of drugs used beyond the label specifications
Among the 107 drugs considered in this study, 43 che-
motherapies and 22 other cancer therapies were admin-
istered to a population of 2,633 breast cancer patients
totaling 14,586 drug encounters. Only 21 (32.3%) of
these therapies were indicated for breast cancer during
the full study period or at the time of their first intro-
duction to the market. Gemcitabine was approved by
the FDA for breast cancer in December 2004. Accord-
ingly, all gemcitabine encounters which occurred before
that date were considered off-label if no indication listed
in Table 1 was diagnosed. It is of note that, although the
FDA revoked breast cancer as an indication for bevacizu-
mab on November 18, 2011 (FDA News Release 2011),
breast cancer was considered a labeled indication from the
original approval date for this indication (February 22,
2008) until the end of the study period. A total of 36 drugs
(55.4% of all cancer therapies administered) were used
either for an off-label indication or by a recipient whose
age differs from the label specifications. A total of 13.0% of
patients received at least one cancer therapy under these
off-label circumstances.
Off-label use by drug category
The frequency of off-label use of chemotherapy and other
drugs was similar (55.8% and 54.5%). However, off-label
patient encounters was almost double for chemother-
apy compared to other drugs (14.1% vs 8.4%) (Table 2).
Topoisomerase inhibitors and alkylating agents were the
classes of chemotherapies with the highest proportion of
off-label use, whereas the targeted agents ranked first for
the other cancer therapies.
Age-related off-label use
Only 8 drugs which we considered had age-related restric-
tions applied by the FDA when they granted approval
(either limiting approval based on age or to a particular
age-related event such as menopause) (Table 3). Most en-
counters with these drugs (96.4%) were in line with the
age-related label specifications. Although clorafarabine is
indicated for use in pediatric patients with acute or relapse
lymphoblastic leukemia, all reported encounters involved
patients over the age of 21 diagnosed with other off-label
indications than breast cancer.Level of evidence
If we only consider therapies not specifically indicated
for the treatment of breast cancer, 55.5% of drug en-
counters recorded in the database can be categorised as
off-label on the basis of indication for use. The drugs
with the highest number of off-label uses were, in de-
scending order, vinorelbine, carboplatin, bevacizumab,
leuprolide, liposomal doxorubicin, and cisplatin (Table 4).
Overall, 93.3% of these off-label drug encounters were
associated with a diagnosis of breast cancer. The pattern
of off label-use appeared to be aligned with the available
evidence to support the use. The level of evidence de-
rived from the drug with the highest off-label use, vino-
relbine, was considered to be sufficient to support its
use in a breast cancer setting. During the study period,
the other five drugs with the highest off-label use were
considered to have limited evidence to support their use
in a breast cancer population, including bevacizumab
which obtained market approval for this indication in
February 2008 and was subsequently revoked by the
FDA in November 2011 after concluding that the drug
has not been shown to be effective or safe for that use.
Patient demographics
The median age of the study population was 59 years.
Drug encounters were more likely to be off-label among
younger women (<50 years age) (16.2%), whereas en-
counters for patients in the older age group (≥75 years)
were less common (7.4%). There were more off-label en-
counters among African American breast cancer pa-
tients and patients with other ethnic backgrounds than
among Caucasian patients (Table 5). There was no ap-
parent relationship between marital status and the off-
label administration of cancer therapies.
Drug characteristics and insurance coverage
Off-label use was inversely related to the number of la-
beled indications specific to the drugs under study.
Drugs with only one or two labeled indications were
more likely to be involved in an off-label drug encoun-
ter. The date of market approval was also predictive of
off-label use, with therapies approved by the FDA be-
tween 1981 and 1990 being more likely to be with linked
to off-label use. The information about drug coverage
plans was missing for a large proportion of encounters
(77.4%); however, considering only encounters for which
insurance information is available, Blue Cross was more
strongly associated with off-label use.
Treatment centre and physician characteristics
Although 114 treatment centres were contributing to
the database at the time of the study, 67 distinct health-
care institutions provided electronic records of drug en-
counters meeting the criteria of the study. Of these
Table 1 Summary of FDA-approved chemotherapeutic agents investigated in current study by category and subcategory
Drug category Drug name Indicated for
breast cancer
Labeled indications if not indicated
for breast cancer (ICD-9 codes)
Initial FDA approval
during study period









Melphalan 183,1 198.6, 1203.0 1964
Oxaliplatin 153,154,197.5 August 2002
Streptozocin 157.4 1982
Thiotepa Yes 1959
Antimetabolites Azacitidine 205,280-285 May 2004
Capecitabine Yes 1998
Cladribine 202.4 1993
Clofarabine 204.0,204.9 December 2004
Cytarabine 204.0, 204.9, 205.0, 205.1, 205.9 1969
Fludarabine 204.1, 204.9 1991
Fluorouracil Yes 1962
Gemcitabine Yes2 157.0-157.9, 162.2-162.5, 162.8, 162.9, 197.03 1996
Hydroxyurea 172.1-172.4, 173.1-173.4, 183, 195.0, 198.2, 198.6, 205.1, 205.9 1967
Mercaptopurine 204.0, 204.9 1953
Methotrexate Yes 1953
Pemetrexed 162.2-162.5, 162.8, 162.9, 163, 197.0 February 2004
Anti-tumor
antibiotics











Mitomycin-C 151, 157 1981
Topoisomerase
inhibitors
Etoposide 162.2-162.5, 162.8, 162.9, 186, 197.0 1983
Irinotecan 153, 154, 197.5 1996
Mitoxantrone 185, 205–208, 340 1987
Topotecan 162.2-162.5, 162.8, 162.9, 180, 183,197.0, 198.6 1996
Anti-mitotic Docetaxel Yes 1996
Ixabepilone Yes October 2007
nab-Paclitaxel Yes January 2005
Paclitaxel Yes 1992
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Table 1 Summary of FDA-approved chemotherapeutic agents investigated in current study by category and subcategory
(Continued)
Vinblastine Yes 1965
Vincristine 171, 189.0, 189.9, 194.0, 194.9, 198.0, 200, 201, 202.0, 202.1, 202.8,
204.0, 204.9
1963
Vinorelbine 162.3-162.5, 162.8, 162.9 1994
1Indication for the oral formulation.
2FDA-approved for breast cancer on December 18, 2004.
3Indications approved by the FDA before December 18, 2004. Ovarian cancer only included after it was approved by the FDA on July 14 2006.
4Not breast cancer specifically but locoregional solid tumors.
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cordance with the label specifications (66 centres), while
47 centres dispensed at least one therapy under off-label
circumstances. This practice was more common in treat-
ment centres located in the Northeastern region of the
United States, whereas institutions in the Midwest were
less likely report this type of use. Smaller centres with a
limited number of beds were more likely to administer
drugs in an off-label fashion; this practice was less likely
in medium size institutions (199–399 beds). Specialists
were more inclined to prescribe chemotherapies and
other cancer therapies, but none of the physician types
appeared to be associated with increased off-label use.
Discussion
In the present study, 13.0% of women with breast cancer
were prescribed at least one cancer therapy under off-
label circumstances, less than the 35% reported previ-
ously (Dean-Colomb et al. 2009). This difference may be
related to the greater diversity of patients and types of
therapies considered in our investigation, as well as the
disparity between the two study periods. Several drugs
were approved by the FDA between 2002 and 2009, in-
cluding 4 drugs with a labeled breast cancer indication
(bevacizumab, gemcitabine, ixabepilone and nab-
paclitaxel). The introduction of new medications on the
market and the approval of new indications for estab-
lished drugs may also explain the smaller proportion ofTable 2 Number of off-label drugs and encounters for each d
Category Number off-label
drugs (%)1
Off-label encounters (%)2 Sub





Other agents 12 (54.5%) 483 (8.4%) Tar
Imm
Ho
1Expressed as a percentage of all drugs including those indicated for breast cancer
2Expressed as a percentage of all encounters including those indicated for breast cwomen who experienced off-label use in our study, espe-
cially since gemcitabine was listed as the second drug
with the most off-label use in the previous investigation.
In agreement with previous research, vinorelbine demon-
strated the highest proportion of off-label use. Off-label
and subsequently labeled encounters with bevacizumab
was sustained throughout this study. It would be interest-
ing to determine if the use of this drug for treatment of
breast cancer has decreased since the FDA revoked this
indication from the product label on November 18, 2011.
A previous report showed appreciable geographic vari-
ation in prescribing patterns in the US (Wennberg
2004). In the present paper, about two thirds of encoun-
ters were recorded in treatment centres located in the
Northeastern census region, which includes 46 of the
114 treatment centres in the HealthFactTM database.
Since this region represented 19% of the US population
in the 2000 census (United States Census Bureau 2010),
the data may not be fully representative of overall off-
label prescribing practice in the US.
Although specialists were more likely to prescribe can-
cer therapies, no notable differences were observed in
off-label prescribing habits by physician type, an obser-
vation which differs from a previous report which fo-
cused on a pediatric population, a vulnerable subgroup
rarely included in clinical trials (Schrim et al. 2003). Ac-
cordingly, the scarcity of evidence to support pediatric




oisomerase inhibitor 4 (100%) 61 (27.9%)
ylating agents 7 (58.3%) 485 (26.2%)
i-metabolites 8 (61.5%) 103 (8.5%)
i-tumor antibiotics 3 (37.5%) 75 (6.3%)
i mitotics 2 (28.6%) 429 (11.6%)
geted therapies 2 (50.0%) 11 (37.9%)
unotherapies 5 (45.5%) 233 (8.2%)
rmone therapies 5 (62.5%) 239 (8.2%)
in a given therapeutic category or subcategory.
ancer in a given therapeutic category or subcategory.
Table 3 Age as per FDA-approved product label for drugs
under study with such specification









1For the purpose of this study, age of menopause was fixed at 50 years.
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condition, were more inclined to prescribe off-label. Off-
label therapy may also be a last resort for patients exhi-
biting poor prognoses and limited therapeutic options,
regardless of physician type.
Off-label encounters were more common in younger
compared to older patients. There was no apparent rela-
tionship between off-label encounters and marital status,
although off-label encounters were more prevalent
among non-Caucasians. While other studies have shown
racial difference in breast cancer treatment decisions
(Griggs et al. 2007; Maly et al. 2006), the literature is
ambivalent regarding the association between race and
off-label prescribing (Schrim et al. 2003; Maly et al.
2006; Patkar et al. 2007).
As in previous research, we observed that medications
with the fewest labeled indications had the highest rate
of off-label use (Radley et al. 2006). Therapies approved
in the 1980’s were more likely to be used off-label, pos-
sibly because older drugs will have had greater oppor-
tunity for discovery of new evidence to support off-label
use (Demonaco et al. 2006; Eguale et al. 2012). Since
these drugs no longer enjoy patent protection, it is un-
likely that a randomized clinical trial to provide evidence
to support a new indication will be undertaken. Of theTable 4 Level of evidence for the 6 drugs with the highest of
Drugs Total Total off-label (%) BC specific
Vinorelbine 732 413 (27.0%) 395
Carboplatin 444 382 (25.0%) 338
Bevacizumab 132 199 (13.0%) 222
Leuprolide 136 133 (8.7%) 122
Liposomal Doxorubicin 104 67 (4.4%) 59
Cisplatin 68 48 (3.1%) 23
The total number of off-label encounters and percentage of total encounters is liste
use associated to a breast cancer diagnosis were graded as Sufficient, Limited or In
the study period. If the off-label encounter was associated to another condition, the
1All bevacizumab encounters before February 22, 2008.
2Glioblastoma indication approved by FDA (May 05, 2009) after the drug was admin12 new drugs approved by the FDA for the treatment of
cancer between 1981 and 1990, only one was indicated
for breast cancer; this may explain the high off-label use
observed (78.7%) for drugs originally approved during
this decade. Drugs marketed before 1981 were less likely
to be prescribed off-label, even though physicians may
be more familiar with these drugs; these drugs tended to
have a higher number of labeled indications, thereby de-
creasing the likelihood of being prescribed off-label. Pri-
vate insurers such as Blue Cross demonstrated greater
off-label use than public insurers, as reported previously
(Patkar et al. 2007), possibly due to government policies
restricting access to therapies. Although not evaluated in
this article in absence of information on efficacy, the
likelihood of off-label use may also depend on the poten-
tial therapeutic effect of the drug.
Study strengths include (1) the availability of data from
different insurers (2) inclusion of all, not just post-
menopausal, breast cancer patients (3) consideration of
age in determining off-label use, and (4) the investigation
of all approved cancer therapies, not just chemotherapies.
Our study also has a number of limitations. (1) Be-
cause ICD-9-CM codes were used in identifying off-label
use, any underreporting or miscoding could affect the
accuracy of the results. (2) Missing data could influence
the results. For example, information on insurance cover-
age was unavailable for more than 70% of drug encoun-
ters. For the purpose of this study, it was assumed that the
distribution of the missing information was proportional
to that observed within the available data. (3) Since
treatment centres in the Northeast region were overrepre-
sented, results may not be representative of overall off-
label practice in the United States. (4) Since the data were
collected from hospital encounters, this analysis only con-
siders prescriptions filled within the hospital setting; en-
counters with medications dispensed outside of this
setting were not captured. Accordingly, encounters with
oral medications such as endocrine therapies may be un-
derrepresented as these drugs are often administered dailyf-label use
off-label Level of evidence Primary ICD9 diagnosis code
other than BC
Sufficient 147, 184.4, 188, 202.8, 204.1
Limited 147, 162, 182, 191, 202.88, 235.7
Limited 162.9, 184.4, 191.92, 202.8
Limited 171, 173.3
Limited 162.8, 171.9, 202.8
Limited 149.8, 150, 151, 162, 170.3, 173.3,
182, 195.0, 201, 202.8, 203,
d for each drug. The level of evidence and recommendation for the off-label
adequate based on the source and strength of the evidence available during
ICD-9-CM code was recorded.
istered BC = breast cancer.
Table 5 Demographic, treatment centre, insurance
coverage and drug characteristics comparison between
on-label and off-label encounters
Variable Variable category Off-label (%)




Ethnicity* Caucasian 1113 (10.3%)
African American 185 (13.0%)
Other 95 (15.3%)
Unknown 243 (14.4%)
Marital status Married 338 (11.0%)
Other 1293 (11.3%)
Unknown 5 (10.4%)
Prescription drug coverage* Medicare 209 (9.5%)
Medicaid 81 (10.4%)
HMO/PPO 24 (6.9%)

























*Differences amongst categories for this variable are significantly different
(p < 0.00001) based on a chi-square test of homogeneity.
Expressed as the number and percentage of off-label encounters.
Expressed as the number and percentage of off-label encounters.
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used evaluate the significance of differences in off-label
use with respect to the demographic, treatment centre, in-
surance coverage, and drug characteristics in Table 6 do
not take into account the correlation among repeated
encounters with the same patient. However, it is unlikely
that even a high degree of correlation among repeat en-
counters would render these significant differences non-
significant (P > 0.05). (6) The association between different
disease characteristics and off-label use was not assessed
since information on tumor stage, grade, and tumor
markers was unavailable. (7) The definition of off-label
was conservative, since concomitant or sequential medica-
tion (first, second or later line), dosage, frequency, route of
administration, and duration of treatment were not con-
sidered in this analysis.
The specificity of this study to off-label practice in the
US between January 2000 and June 2009 should also be
noted. Off-label prescribing practices may vary from one
jurisdiction to another: although vinorelbine is approved
for use in the treatment of breast cancer in most European
countries, this indication has not yet been approved in
the US.Conclusions
Our study corroborates and expands on previous find-
ings to suggest that off-label use of cancer therapies is
widespread among patients with breast cancer and that
the majority of these encounters have some evidence
to support their use. Socio-demographic, insurance
coverage, treatment center, and physician and drug
characteristics appeared to influence off-label prescrib-
ing patterns. More research is warranted to determine
whether the practice of off-label prescribing in the
context of cancer treatment yields substantial clinical
benefits. In the interim, decisions to prescribe a ther-
apy under off-label circumstances should be evidence-
based in an effort to achieve therapeutic benefit and to
minimize the risk of possible adverse reactions associ-
ated with these therapies.Methods
Data source
All female patients from the Cerner HealthFactsTM data
warehouse diagnosed with breast cancer (ICD-9-CM
174, 238.3, 239.3) from January 2000 to June 2009 who
received at least one cancer therapy in a hospital setting
during this period were considered for inclusion in this
study. At the time of the analysis, HealthFactsTM con-
tained information on distinct inpatient admissions,
emergency department, and outpatient visits from 114
hospitals and clinics throughout the United States.
Table 6 Summary of other FDA-approved anticancer therapies investigated in current study by category and
subcategory
Drug category Drug name Indicated for breast cancer Labeled indications if not indicated for








Fulvestrant Yes April 2002
Goserelin Yes 1989
Letrozole Yes 1997




Bortezomib No May 2003
Erlotinib No November 2004
Imatinib No 150-154, 158.0, 159.0, 159.8, 159.9, 171.5-171.9,
205.1, 205.9, 238.1, 239
May 2001
Sorafenib No 155.0, 155.2, 197.7, 189.0, 189.8, 189.9, 198.0 December 2005
Immunotherapies Aldesleukin No 172, 189.0, 189.1, 189.8, 189.9, 198.0, 198.2 1992
Alemtuzumab No 204.1, 204.9 May 2001
Bevacizumab Yes1 153, 154, 162.2-162.5, 162.8, 162.9, 191, 197.0,
197.5, 198.3
February 20042
Cetuximab No 140-149, 153, 154, 160, 161, 173.0-173.4, 195.0,
197.5
February 2004
Denileukin diftitox No 202.1, 202.2 1999
Gemtuzumab
ozogamicin
No 205.0, 205.9 2000
Panitumumab No 153, 154, 197.5 September 2006
Rituximab3 No 200, 202, 204.1, 204.9, 714 1997
Thalidomide No 0.17.1, 695.2, 203.0 1998
Trastuzumab Yes 1998
1Breast cancer indication approved by FDA on February 22, 2008 and revoked in November 2011.
2Colorectal cancer indication approved in February 2004, Non-small cell lung carcinoma in October 2006, Glioblastoma in May 2009.
3Obtained FDA approval for Wegener’s Granulomatosis (WG) and Microscopic Polyngiitis (MPA) only in April 2011 (post-study period).
Hamel et al. SpringerPlus  (2015) 4:209 Page 7 of 9Study eligibility criteria
For each patient, the date of the earliest breast cancer
diagnosis was designated as the index date. Those who
had less than 6 months recorded care prior to the index
date were excluded because they were considered less
likely to have their breast cancer therapies and potential
comorbidities completely recorded. The study was limited
to those at least 20 years of age as of their index date.
Identification of anticancer therapy under study
Any medication approved by the FDA during the follow-
up the period for its anticancer properties was consid-
ered for inclusion and was classified as chemotherapy,
targeted therapy, hormone therapy, or immunotherapy
based on its mechanism of action as per Table 7. The
chronological FDA-approval history for each drug in a
given therapeutic class was validated through the FDA’sDrug Approvals and Databases. To be considered, the
drug and its labeled indications had to be endorsed by
the FDA at the time of the study. Drugs and indications
that were approved during the study period were also
included.
Determination of off-label status
For the purpose of this study, we ascribed off-label sta-
tus to all drug uses which met at least one of the follow-
ing criteria: (1) none of the ICD-9-CM codes in the
patient’s electronic record during the study period could
be matched to any labeled indications of the prescribed
drug (Table 1 and Table 6), or (2) the age of the recipient
differs from the label specifications (Table 3). An attained
age of 50 years was used as an indicator of post-
menopausal status as described elsewhere (Lenz et al.
2002; La Vecchia et al. 1997; Kreiger et al. 1992). Off-label
Table 7 Categories and subcategories of cancer drugs considered for analysis
Category Subcategory
Chemotherapies Alkylating agents, Antimetabolites, Anti-tumor antibiotics, Topoisomerase inhibitors, Anti-mitotic agents
Hormone therapies Estrogen receptor modulators, Aromatase inhibitors, anti-Androgens
Targeted thrapies Small-molecule inhibitors, Differentiating agents
Immunootherapies Monoclonal antibodies, Non-specific Immunotherapies andadjuvants, Immunomodulators
All therapies in these categories and subcategories that were FDA-approved for a cancer indication during the study period were evaluated.
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second or later line), dosage, duration of treatment, or
route of administration were not considered. The main
source for determining labeled indications were the drug
labels at the time of use found on the FDA website.
For each drug encounter, all associated ICD-9-CM
codes, regardless of their diagnostic priority, were con-
sidered to determine the indication for use. If none of
the ICD-9-CM codes specific to the drug encounter
were labeled indications, the overall ICD-9-CM diagno-
sis information for the patient was investigated. If the
patient had never been diagnosed with a condition ap-
proved by the FDA for the specific drug, the use was
considered off-label. Encounters with drugs that have
obtained FDA approvals for new indications during the
study period were considered off-label before the official
approval date. For labeled indications that could not be
accurately coded using the ICD-9-CM system, all codes
related to the condition were adopted. For example,
since no official ICD-9-CM diagnosis codes exist to spe-
cify cancer subtypes expressing a particular tumor
marker, the ICD-9-CM codes for breast cancer (ICD-9-
CM 174, 238.3, 239.3) were considered labeled indica-
tions for therapies indicated for breast cancer tumors
overexpressing Her-2. Drugs considered and approved
by the FDA at the time of study but not prescribed to
the studied patient population are listed in Table 8.
Level of evidence
The six drugs with the highest off-label use were sub-
jected to a more detailed investigation. The off-label uses
were categorised as breast cancer specific if (1) a breast
cancer diagnosis was associated with the drug encounter,
and (2) no other malignancies or known labeled condi-
tions were diagnosed as part of the same encounter
(excluding secondary malignant neoplasms defined byTable 8 Other FDA-approved anti-cancer therapies at the tim
Category Drug name
Chemotherapies Altretamine, Asparaginase, Bendamustine,
Lomustine, Nelarabine, Pegaspargase, Pen
Hormone therapies Bicalutamide, Degarelix, Flutamide, Histreli
Targeted therapies Dasatinib, Everolimus, Lapatinib, Nilotinib,
Immunotherapies BCG, Ibritumomab, Imiquimod, InterferonICD-9-CM 196–198). An extensive search of Medline,
U.S. FDA clinical reviews, and drug/disease-state data-
bases (UptoDate online, MICROMEDEX) was con-
ducted to further characterize the level of evidence for
the off-label uses. All six drugs investigated had evidence
derived from at least one well-designed randomized,
phase III clinical trial (RCT) in a breast cancer popula-
tion. All applicable published evidence derived from
these RCTs, including those with negative or equivocal
findings, were used to rate the overall evidence available
for each off-label drug-indication pair. Categorization of
available evidence was conducted independently by two
of the authors (SH and DM) as well as an independent
reviewer using the following three tiered approach: 1)
'sufficient” evidence was derived when at least five RCTs
reported reasonable evidence of therapeutic benefit in
breast cancer setting; 2) 'limited" evidence was extracted
from at least one RCT but the conclusions from overall
findings are inconsistent; and 3) 'inadequate’ evidence
was derived when no RCT reported benefit or non-
inferiority when compared to the standard chemother-
apy regimen.
Statistical analysis
The level of off-label use was calculated by dividing the
number of off-label drug encounters by the total number
of encounters for a given drug and therapeutic class.
Additionally, the number of drugs used under off-label
circumstances was calculated using all drugs within a
given therapeutic category or subcategory as a denomin-
ator. Variation in the percentage of off-label encounters
with patient age, ethnicity, marital status, source of pay-
ment, census region, bed size range, physician’s specialty,
the date of market approval for a drug, and the number
of approved indications was examined using chi-squaree of study but not used in the studied population
Busulfan, Decitabine, Estramustine, Floxuridine, Liposomal Cytarabine,
tostatin, Procarbazine, Temozolomide, Teniposide, Thioguanine, Valrubicin
n, Nilutamide, Toremifene, Triptorelin
Sorafenib, Temsirolimus, Vironostat. Bexarotene, Tretinoin
alfa-2a, Lenalidomide, Tositumomab
Hamel et al. SpringerPlus  (2015) 4:209 Page 9 of 9tests. All analyses were conducted using SAS software
(Version 9.2, SAS Institute, Cary, NC).
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